Basal Cell Carcinoma Clinical Trial
Official title:
A Randomized Clinical Trial in the Surgical Treatment of Basal Cell Carcinoma of the Eyelid: Surgical Excision With Frozen Section vs. Permanent Section Control
This study is an equivalency study designed as a randomized clinical trial. Patients with a biopsy proven nodular periocular basal cell carcinoma (BCC) who have agreed to have surgical excision will be eligible. Study patients will undergo surgical excision of the lesion and then be randomized to having frozen section or permanent section pathological control. For those patients randomized to permanent section control the sample will be sent to pathology and surgical reconstruction will be performed. Patients randomized to frozen section will have additional margins re-excised before reconstruction depending on the pathologic results. Tumor clearance rates after surgical excision will be compared between the two techniques as a primary study question. Patients will be followed long-term to determine recurrence rates in the two groups. The study is designed to determine if the two techniques are equivalent within a given margin of error with respect to outcome measures.
Basal cell carcinoma (BCC) accounts for 80-90% of skin cancers and is the most common skin
cancer of the periocular region. Surgical excision is considered the gold-standard in
therapy. Previous literature has shown comparable recurrence rates of BCC between surgical
excision with frozen section control and surgical excision and permanent section control. To
data, there are no prospective studies comparing frozen section control with permanent
section control. We hypothesize that short term tumor clearance rates between frozen section
and permanent section control will be similar and that long-term tumor recurrence rates will
be similar between the two techniques. If we find that these two treatment options are
equivalent with respect to margin control and recurrence rates, then considerable time and
money savings can be accrued through using permanent section control amongst patients with
periocular BCC.
The study design is a single-blind randomized controlled trial. Patients who have already
agreed to surgical excision of nodular type periocular BCC will be eligible. All patients
will undergo a detailed informed consent process. All patients will undergo a punch biopsy
to confirm the histopathological diagnosis of BCC. The study design will be a
single-blinded, randomized clinical trial. Statistically, the study will be designed as an
equivalency study. Prior to randomization the BCC will be excised with 3mm clinical margins
in a standard fashion. Subjects will then be randomized to one of two groups: 1. Frozen
section control; 2. Permanent section control. For those patients randomized to permanent
section control the clinical sample will be sent for pathologic analysis and surgical
reconstruction will be performed immediately using standard oculoplastic techniques.
Patients randomized to frozen section will have additional margins re-excised if necessary
depending on the pathologic results. Oculoplastic reconstruction will be performed after all
margins are clear. Patients will undergo examinations at the following times to assess for
clinical recurrence: 1. 2 weeks and as necessary thereafter to assess surgical result and
wound healing, 2. 6 months, 3. 1 year, 4. yearly up to 5 years.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04552990 -
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT04229277 -
Fast Track Diagnosis of Skin Cancer by Advanced Imaging
|
N/A | |
Completed |
NCT05608902 -
Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
|
||
Completed |
NCT05077033 -
Intratumoral phIL12 GET
|
Phase 1 | |
Active, not recruiting |
NCT04928222 -
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04929535 -
Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment
|
Phase 2 | |
Completed |
NCT02662244 -
Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
|
N/A | |
Completed |
NCT00959647 -
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
|
Phase 2 | |
Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
Completed |
NCT00473343 -
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT06024629 -
cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
|
||
Not yet recruiting |
NCT05324202 -
New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management
|
N/A | |
Withdrawn |
NCT04099446 -
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
|
||
Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
Completed |
NCT01201915 -
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01208831 -
An East Asian Study of LDE225
|
Phase 1 | |
Completed |
NCT01260987 -
Fractional CO2 Laser Assisted Photodynamic Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT01014819 -
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
|
N/A | |
Completed |
NCT00472043 -
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma
|
Phase 3 |